Multiple endocrine neoplasia type 2 (MEN 2) is a rare inherited condition that causes tumors to develop in hormone-producing glands, particularly the thyroid and adrenal glands. It affects roughly 1 in 35,000 people worldwide and is caused by mutations in a single gene called RET, which is passed from parent to child. The hallmark of MEN 2 is medullary thyroid cancer, which develops in nearly all carriers of the gene mutation at some point in their lives.
The Three Subtypes of MEN 2
MEN 2 is divided into subtypes based on which combination of tumors and features a person develops. Understanding the subtype matters because it determines how aggressive the disease is and how early treatment needs to begin.
MEN 2A is by far the most common form, accounting for 60% to 90% of all MEN 2 cases. It typically involves medullary thyroid cancer as the first sign, along with a possible adrenal gland tumor called a pheochromocytoma and overactive parathyroid glands. Parathyroid involvement tends to be mild, often showing up only as a slight elevation in calcium on blood work without causing noticeable symptoms. A small number of people with MEN 2A also develop a skin condition on the upper back (cutaneous lichen amyloidosis) that can appear even before any thyroid problems. Rarely, MEN 2A can also overlap with Hirschsprung disease, a condition affecting the nerves of the large intestine.
MEN 2B is the rarest and most aggressive subtype, making up about 5% of cases. It causes medullary thyroid cancer at a very young age, sometimes in infancy. Children with MEN 2B often have distinctive physical features: small, painless bumps called neuromas on the tongue, lips, and inside the mouth, along with a tall, thin body type with long arms and legs relative to their torso (seen in about 75% of patients). Pheochromocytomas occur in roughly half of MEN 2B cases, and about half of those are in both adrenal glands. Parathyroid disease is very uncommon in this subtype.
Familial medullary thyroid carcinoma (FMTC) is now classified as a subtype of MEN 2A. In FMTC, families carry the RET mutation but develop only medullary thyroid cancer, without pheochromocytoma or parathyroid disease. Up to 50% of MEN 2A cases fall into this category. However, the current thinking is that FMTC may simply represent a delayed version of MEN 2A rather than a truly separate condition, so people with FMTC are still screened for adrenal and parathyroid problems throughout their lives.
How the RET Gene Mutation Works
MEN 2 is caused by inherited mutations in the RET gene, which normally helps regulate cell growth. When this gene is mutated, it sends a constant “grow” signal to certain cells, driving tumor formation. The exact location of the mutation within the gene determines which subtype of MEN 2 a person develops and how aggressively the thyroid cancer behaves.
People with MEN 2A typically have mutations in specific regions of the gene (codons 609, 610, 611, 618, 620, or 634). Over 95% of MEN 2B patients have a mutation at a different spot (codon 918), which sits in the part of the gene controlling an enzyme involved in cell signaling. This particular mutation is associated with the earliest and most aggressive thyroid cancers. FMTC families tend to carry mutations in yet another set of locations. The International RET Mutation Consortium used these correlations to create risk categories that guide treatment decisions, particularly the timing of preventive thyroid surgery.
Medullary Thyroid Cancer: The Central Concern
Medullary thyroid cancer is the primary threat in all forms of MEN 2 and the leading cause of death when the condition goes undiagnosed. Unlike the more common types of thyroid cancer, medullary thyroid cancer arises from specialized cells in the thyroid that produce a hormone called calcitonin. Elevated calcitonin levels in the blood serve as an early warning sign and are used as a key marker for diagnosis and monitoring.
The timing of cancer development varies dramatically by subtype. In MEN 2B, medullary thyroid cancer can appear in the first year of life. In high-risk MEN 2A cases (particularly those with codon 634 mutations), cancer typically develops in childhood. In lower-risk mutations, it may not appear until adulthood. This wide range is why genetic testing and identifying the specific mutation are so important: they tell doctors how urgently to act.
Preventive Thyroid Surgery
Because medullary thyroid cancer is virtually certain to develop in someone carrying a RET mutation, removing the thyroid before cancer takes hold is the most effective strategy. The American Thyroid Association recommends timing this surgery based on the specific mutation a person carries.
For the highest-risk mutations (MEN 2B, codon 918), preventive thyroid removal may be recommended as early as the first year of life. For high-risk MEN 2A mutations, particularly codon 634, the guideline is total thyroidectomy by age 5. For people with moderate-risk mutations, an alternative approach involves close monitoring with regular blood tests and neck ultrasounds, with surgery triggered when calcitonin levels begin to rise rather than at a fixed age. Research from surveillance programs has shown this “watchful” approach can be safe for moderate-risk carriers, reducing the years of medical intervention while still catching cancer before it spreads.
Pheochromocytoma: Adrenal Gland Tumors
Pheochromocytomas are tumors of the adrenal glands that produce excess adrenaline and related hormones. In MEN 2, these tumors tend to be different from the sporadic type: they are more often found in both adrenal glands, can be multifocal, and are surrounded by areas of overactive adrenal tissue. Symptoms include episodes of high blood pressure, rapid heartbeat, sweating, headaches, and anxiety, though some pheochromocytomas are found through screening before symptoms appear.
Screening for pheochromocytoma involves blood or urine tests measuring breakdown products of adrenaline. For children with high-risk RET mutations, annual screening begins by age 11. Those with moderate-risk mutations start annual screening at age 16. Detecting a pheochromocytoma before any planned surgery is critical, because the sudden flood of hormones during an operation on an undiagnosed tumor can be life-threatening.
Hyperparathyroidism in MEN 2A
About 20% to 30% of people with MEN 2A develop overactive parathyroid glands, which regulate calcium levels in the blood. In most cases, the condition is mild and discovered through routine blood work showing slightly elevated calcium rather than through symptoms like kidney stones or bone thinning. When surgery is needed, the approach depends on how many of the four parathyroid glands are affected: sometimes only one gland is removed, while other cases call for removing most or all of the glands with a small piece transplanted elsewhere in the body to maintain calcium regulation.
Genetic Testing for Family Members
MEN 2 follows an autosomal dominant inheritance pattern, meaning each child of an affected parent has a 50% chance of inheriting the mutation. Current guidelines call for genetic testing of all first-degree relatives (parents, siblings, and children) whenever a RET mutation is identified in a family. Testing can be done with a simple blood draw at any age, including in newborns when the family carries a high-risk mutation.
For relatives who test positive but have no signs of disease yet, the path forward depends on their specific mutation. High-risk carriers are typically directed toward early preventive surgery. Moderate-risk carriers may enter a surveillance program with blood tests and imaging every 6 to 12 months, with surgery planned if calcitonin levels start climbing. Relatives who test negative for the family’s known mutation can be released from the screening program entirely, which is a significant relief given the lifelong monitoring that carriers require.
Living With MEN 2
After thyroid removal, people with MEN 2 take daily thyroid hormone replacement for the rest of their lives. If one or both adrenal glands are removed for pheochromocytoma, steroid hormone replacement may also be necessary. Beyond these medications, ongoing surveillance is a permanent part of life: regular calcitonin levels to watch for any recurrence of thyroid cancer, periodic screening for pheochromocytoma, and calcium monitoring for those with MEN 2A.
Outcomes depend heavily on when the condition is caught. When medullary thyroid cancer is removed before it has spread beyond the thyroid, the prognosis is excellent. When it is found late, after it has reached lymph nodes or distant organs, treatment becomes much more difficult. This is the core reason genetic testing and early intervention are so emphasized in MEN 2 families: catching the disease before it declares itself clinically is the single biggest factor in long-term survival.